ISSN:
1468-2982
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
This multicentre, double-blind, randomized, placebo-controlled, parallel study was designed to evaluate the efficacy of combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP) in the acute treatment of migraine attacks. A total of 266 patients, 18–65 years old, with two to six attacks of migraine with or without aura (IHS criteria) per month were included. The patients had to treat two migraine attacks with LAS-MCP (1620 mg lysine acetylsalicylate-the equivalent of 900 mg aspirin- combined with 10 mg metoclopramide) or placebo. The main outcome measure was headache relief (reduction in headache severity from grade 3 or 2-severe or moderate-to grade 1 or 0-mild or none) 2 h after treatment. LAS-MCP was superior to placebo for headache relief (56% vs 28%) and for the following secondary outcome measures: complete headache relief (18% vs 7%; p 〈 0.001), nausea (28% vs 44%; p 〈 0.001), vomiting (3% vs 11%; p = 0.001), use of rescue medication (47% vs 68%; p 〈 0.001), global efficacy judged as good or excellent (32% vs 14%; p 〈 0.001). The tolerability was considered as good in 94% of treated attacks in both groups. Combined oral lysine acetylsalicylate and metoclopramide is an effective and well-tolerated acute treatment of migraine attacks.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1046/j.1468-2982.1994.1404297.x
